| Dr Lisa A Simmon, MD | |
|
5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 | |
| (602) 865-2627 | |
| (602) 865-2632 |
| Full Name | Dr Lisa A Simmon |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 5555 W. Thunderbird, Glendale, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922430008 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 50672 (Arizona) | Primary |
| 207R00000X | Internal Medicine | 50672 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner Hospital Based Physicians Arizona Llc | 3274782487 | 398 |
News Archive
As part of the National Blueprint for Injury Prevention in Older Drivers, the Canadian Association of Occupational Therapists (CAOT) has released some important new resources for drivers, their families and health care professionals. A series of information brochures and website (www.olderdriversafety.ca) promoting older driver safety were unveiled today at a public forum held at Ottawa's Good Companions Senior Centre.
Cancer Research UK scientists have discovered that a gene called POLQ is linked to an eight-fold risk of breast cancer returning. Developing drugs to block POLQ could increase survival and stop the cancer coming back, according to research published in OncoTarget.
Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.
› Verified 3 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
As part of the National Blueprint for Injury Prevention in Older Drivers, the Canadian Association of Occupational Therapists (CAOT) has released some important new resources for drivers, their families and health care professionals. A series of information brochures and website (www.olderdriversafety.ca) promoting older driver safety were unveiled today at a public forum held at Ottawa's Good Companions Senior Centre.
Cancer Research UK scientists have discovered that a gene called POLQ is linked to an eight-fold risk of breast cancer returning. Developing drugs to block POLQ could increase survival and stop the cancer coming back, according to research published in OncoTarget.
Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lisa A Simmon, MD 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Ph: (602) 865-2627 | Dr Lisa A Simmon, MD 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Ph: (602) 865-2627 |
News Archive
As part of the National Blueprint for Injury Prevention in Older Drivers, the Canadian Association of Occupational Therapists (CAOT) has released some important new resources for drivers, their families and health care professionals. A series of information brochures and website (www.olderdriversafety.ca) promoting older driver safety were unveiled today at a public forum held at Ottawa's Good Companions Senior Centre.
Cancer Research UK scientists have discovered that a gene called POLQ is linked to an eight-fold risk of breast cancer returning. Developing drugs to block POLQ could increase survival and stop the cancer coming back, according to research published in OncoTarget.
Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.
› Verified 3 days ago
Ipuole Paulinus Ogar, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2632 | |
Shiva Shojaie, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
Dr. Veenu Gill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5620 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-795-7256 Fax: 602-795-7257 | |
Michael Best, M.D., MPH Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
Hasan Chaudhry, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 20118 N 67th Ave Ste 300-415, Glendale, AZ 85308 Phone: 602-736-8386 | |
Dr. Firoozeh Isfahani, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2631 | |
Dr. Matthew Brownell, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W, Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2632 |